Eli Lilly CEO expects new weight loss pill to be approved next year
Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...
STAT25d
Eli Lilly’s obesity drug Zepbound approved to treat sleep apnea in U.S.
The Food and Drug Administration on Friday cleared Eli Lilly’s obesity drug Zepbound as the first treatment for a common sleep disorder in the U.S. Zepbound, whose scientific name is ...
Lilly asked Feds to pause drug pricing negotiations: report
Eli Lilly (LLY) has reportedly asked the Biden administration to pause negotiations with drugmakers over pricing, citing ...
CNBC on MSN24d
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...
FiercePharma12d
Lilly’s Zepbound expected to surpass Novo’s Wegovy to ‘dominate’ obesity market: GlobalData
The company is also testing tirzepatide in heart failure ... said in the report. “Now with Zepbound, the revolution ...
FierceBiotech21h
Kailera reports Zepbound-rivaling weight loss in phase 2 obesity trial
Fresh from a $400 million series A round, Kailera Therapeutics has shown off phase 2 data on an obesity candidate it believes ...
Eli Lilly and Company (NYSE:LLY) Shares Acquired by Czech National Bank
Czech National Bank boosted its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 6.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange ...
Yahoo Finance3d
Eli Lilly and Company (LLY)
While Eli Lilly and Company ( NYSE:LLY ) shareholders are probably generally happy, the stock hasn't had particularly... The U.S. Food and Drug Administration (FDA) recently approved Zepbound ...
Flynn: Eli Lilly could capture a significant part of a $100 billion market with Zepbound.
Terence Flynn, Biotech Analyst at Morgan Stanley, discusses Eli Lilly's recent stock boost and its designation as Morgan ...